LYRA THERAPEUTICS INC (LYRA)

Company Profile

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Company Info

LYRA THERAPEUTICS INC

480 Arsenal Way

Watertown MASSACHUSETTS 02472

P: 16173734600

CEO: Maria Palasis

Employees: 109

Website: https://lyratherapeutics.com/